Drug resistance in DNA repair defective ovarian cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1076048

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and respond to new PARP inhibitor therapy, yet even then the cancer often recurs. I will use a new model to study human ovarian cancers in mice. My focus will be understanding resistance to PARP inhibitors in individual ovarian cancers and designing approaches to overcome this resistance.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2016

Funding Scheme: NHMRC Postgraduate Scholarships

Funding Amount: $122,032.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

DNA repair | drug resistance | drug screening | genetic testing | ovarian cancer

Related Links